<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="bietti-cd" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">bietti-cd</book-part-id>
      <title-group>
        <title>Bietti Crystalline Dystrophy</title>
        <alt-title alt-title-type="alt-title">Synonyms: Bietti Crystalline Corneoretinal Dystrophy, Bietti Crystalline Retinopathy</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Okialda</surname>
            <given-names>Krystle A</given-names>
          </name>
          <degrees>BS</degrees>
          <email>kokialda@u.washington.edu</email>
          <aff>Department of Pharmaceutics<break/>University of Washington<break/>Seattle, Washington</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Stover</surname>
            <given-names>Niamh B</given-names>
          </name>
          <degrees>MS, CGC</degrees>
          <email>niamh.stover@gmail.com</email>
          <aff>Genetic Counselor<break/>Banner Health<break/>Glendale, Arizona</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Weleber</surname>
            <given-names>Richard G</given-names>
          </name>
          <degrees>MD, DABMG, FACMG</degrees>
          <email>weleberr@ohsu.edu</email>
          <aff>Ophthalmic Genetics Clinic<break/>Casey Eye Institute<break/>Oregon Health Sciences University<break/>Portland, Oregon</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kelly</surname>
            <given-names>Edward J</given-names>
          </name>
          <degrees>PhD</degrees>
          <email>edkelly@u.washington.edu</email>
          <aff>School of Pharmacy<break/>University of Washington<break/>Seattle, Washington</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2012-04-12" date-type="created">
          <day>12</day>
          <month>4</month>
          <year>2012</year>
        </date>
        <date iso-8601-date="2012-06-14" date-type="revised">
          <day>14</day>
          <month>6</month>
          <year>2012</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="b-thal" document-type="chapter">Beta-Thalassemia</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="biotin" document-type="chapter">Biotinidase Deficiency</related-object>
      <abstract id="bietti-cd.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Bietti crystalline dystrophy (BCD) is a chorioretinal degeneration characterized by the presence of yellow-white crystals and/or complex lipid deposits in the retina. Progressive atrophy and degeneration of the retinal pigment epithelium (RPE)/choroid lead to symptoms similar to those of other forms of retinal degeneration that fall under the category of retinitis pigmentosa and allied disorders, namely: reduced visual acuity, poor night vision, abnormal retinal electrophysiology, visual field loss, and often impaired color vision. Marked asymmetry between eyes is common. Onset is typically during the second to third decade of life, but ranges from the early teenage years to beyond the third decade. With time, loss of peripheral visual field, central acuity, or both result in legal blindness in most, if not all, affected individuals.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis is based on the finding of numerous small, glistening yellow-white retinal crystals associated with atrophy of the RPE, pigment clumps, and sclerosis of the choroidal vessels; variable crystalline deposits in the corneal limbus; varying degrees of rod and cone dysfunction on electroretinography (ERG); visual field defects; and reflective dots visualized by spectral domain optical coherence tomography (sdOCT). <italic toggle="yes">CYP4V2</italic> is the only gene in which mutations are known to cause BCD.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Referral to low vision specialists and organizations/professionals trained to work with the visually impaired.</p>
          <p><italic toggle="yes">Surveillance:</italic> Periodic ophthalmologic examination to monitor disease progression and periodic visual field testing particularly as it relates to determination of driving eligibility and eligibility for government programs and/or disability.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>BCD is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family are known. </p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="bietti-cd.Diagnosis">
        <title>Diagnosis </title>
        <sec id="bietti-cd.Clinical_Diagnosis">
          <title>Clinical Diagnosis </title>
          <p>The diagnosis of Bietti crystalline dystrophy (BCD), a chorioretinal degeneration, is based on the clinical findings of the typical crystalline deposits in the cornea and retina. BCD is one of few ocular diseases for which the diagnosis can be made with a high degree of confidence by careful examination alone. The diagnosis can be confirmed by the finding of disease-associated variants in <italic toggle="yes">CYP4V2.</italic></p>
          <p>The following features suggest the diagnosis:</p>
          <p><bold>Retina.</bold> Numerous small, glistening yellow-white crystals are scattered throughout the posterior pole and sometimes extend to the midperiphery. The crystalline deposits are associated with atrophy of the retinal pigment epithelium (RPE) and choriocapillaris, pigment clumping, and sclerosis of the choroidal vessels.</p>
          <p>The crystalline deposits have been observed to diminish or even disappear in areas of severe chorioretinal atrophy, as the disease progresses to later stages [<xref ref-type="bibr" rid="bietti-cd.REF.chen.2008.237">Chen et al 2008</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.xiao.2011.181">Xiao et al 2011</xref>]. Areas in which crystals are still present may represent retina that is still only mildly degenerated or in the progress of degenerating [<xref ref-type="bibr" rid="bietti-cd.REF.kojima.2012.390">Kojima et al 2012</xref>]. </p>
          <p>Fluorescein angiography reveals patchy hypofluorescent areas of RPE and choriocapillaris atrophy and a generalized disturbance of the RPE. </p>
          <p><bold>Cornea.</bold> Crystalline deposits in the corneal limbus have been estimated to occur in one quarter to one third of persons with BCD [<xref ref-type="bibr" rid="bietti-cd.REF.kaiserkupfer.1994.569">Kaiser-Kupfer et al 1994</xref>]. It has also been reported that corneal deposits may be more common in persons of northern European background than in Asians [<xref ref-type="bibr" rid="bietti-cd.REF.traboulsi.1987.156">Traboulsi &#x00026; Faris 1987</xref>]. </p>
          <p>If present, the deposits can usually be seen on slit-lamp examination. However, some crystals may be so fine as to go undetected unless specifically and carefully sought; <xref ref-type="bibr" rid="bietti-cd.REF.takikawa.1992.969">Takikawa et al [1992]</xref> suggest that in some individuals with BCD, corneal crystalline deposits may be too subtle to detect on slit-lamp examination. Spectral microscopy may be more appropriate in such cases. </p>
          <p><bold>Electrophysiology.</bold> The <bold>full-field electroretinogram (ffERG)</bold> can show varying degrees of rod and cone dysfunction, ranging from normal to reduced amplitudes of scotopic and photopic responses to undetectable responses [<xref ref-type="bibr" rid="bietti-cd.REF.usui.2001.395">Usui et al 2001</xref>]. Thus, electrophysiologic studies are not necessary to establish the diagnosis of BCD; however, they are useful for establishing the magnitude and extent of retinal degeneration. </p>
          <p>Although studies have shown that the ffERG responses seem to correlate well with stages of disease severity [<xref ref-type="bibr" rid="bietti-cd.REF.usui.2001.395">Usui et al 2001</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.lee.2005.3812">Lee et al 2005</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.mansour.2007.680">Mansour et al 2007</xref>], this is not always the case: </p>
          <list list-type="bullet">
            <list-item>
              <p>The ffERG can remain normal even in later stages of the disease. Normal ffERG responses in individuals with BCD with severe atrophy of the RPE and choroid suggest that the neural retina may remain viable despite disruption to retinal lamination [<xref ref-type="bibr" rid="bietti-cd.REF.rossi.2011.118">Rossi et al 2011</xref>].</p>
            </list-item>
            <list-item>
              <p>Regional forms of BCD that may have normal full-field ERGs have been identified [<xref ref-type="bibr" rid="bietti-cd.REF.wilson.1989.213">Wilson et al 1989</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.weleber.1991">Weleber &#x00026; Wilson 1991</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.rossi.2011.118">Rossi et al 2011</xref>]</p>
            </list-item>
          </list>
          <p><bold>A multi-focal electroretinogram (mfERG)</bold> may detect regional areas of abnormal retinal function when the ffERG is normal, particularly in those regional phenotypes that predominantly affect the posterior pole. </p>
          <p>This degree of variation of electrophysiology may be the result of testing at different stages of disease progression. This variability may also reflect variation in loss of function in the gene product, with alleles with residual function associated with greater retention of ffERG amplitudes. </p>
          <p><bold>Optical coherence tomography (OCT).</bold> Spectral domain OCT (sdOCT) is of value for both diagnosis and management of BCD. </p>
          <p>With improved OCT technology, the integrity of retinal structure can be visualized in persons with BCD, including the hyper-reflective dots thought to represent the crystalline deposits. The majority of OCT studies report that the crystalline deposits appear to reside in the RPE-choriocapillaris complex [<xref ref-type="bibr" rid="bietti-cd.REF.pennesi.2010.531">Pennesi &#x00026; Weleber 2010</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.padhi.2011.199">Padhi et al 2011</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.kojima.2012.390">Kojima et al 2012</xref>]. </p>
          <p>In addition to the crystalline deposits, other reflective spots of various shapes (called retinal tubulation by <xref ref-type="bibr" rid="bietti-cd.REF.zweifel.2009.1596">Zweifel et al [2009]</xref>) can be seen by OCT. <xref ref-type="bibr" rid="bietti-cd.REF.kojima.2012.390">Kojima et al [2012]</xref> reported the presence of spherically shaped, hyper-refractive structures in the outer nuclear layer (ONL) of the retina, particularly located in areas of RPE atrophy. Of note, <xref ref-type="bibr" rid="bietti-cd.REF.kojima.2012.390">Kojima et al [2012]</xref> also observed these same circular structures, but less frequently, in retinal dystrophies other than BCD. </p>
          <p>The degeneration in BCD seen by OCT is most prominent in the outer retina, including the photoreceptor layer, but the degeneration was not uniformly distributed. </p>
          <p><bold>Vision impairment.</bold> The majority of affected individuals have onset of disease during the second or third decade of life; however, age of onset, presenting symptoms, and disease severity vary widely. Marked asymmetry between eyes is common. Symptoms include:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Visual field loss</bold> (progressive). Visual field loss may manifest in different individuals as peripheral field loss (ring, paracentral, or central scotoma) or central or pericentral scotomas (usually associated with atrophic lesions that encroach upon the foveal region of the macula).</p>
            </list-item>
            <list-item>
              <p><bold>Nyctalopia</bold> (progressive). Night blindness (i.e., difficulty seeing in low light) is a nonspecific feature of BCD in that it is typical of many forms of inherited retinal degeneration. </p>
            </list-item>
            <list-item>
              <p><bold>Reduction in visual acuity</bold> (progressive). Visual acuity can range from normal to hand motion (HM). Although the reduction in visual acuity has been reported to typically result in legal blindness by the fifth or sixth decade, central vision can sometimes be spared even in persons with severe disease. More often loss of central visual acuity reflects atrophy or degenerative change close to or including the fovea.</p>
            </list-item>
          </list>
        </sec>
        <sec id="bietti-cd.Molecular_Genetic_Testing">
          <title>Molecular Genetic Testing </title>
          <p><bold>Gene.</bold>
<italic toggle="yes">CYP4V2</italic> is the only gene in which mutation is known to cause Bietti crystalline dystrophy.</p>
          <p>
            <bold>Clinical testing</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Sequence analysis.</bold> Pathogenic variants in <italic toggle="yes">CYP4V2</italic> have been reported in a high percentage of persons with Bietti crystalline dystrophy in China and Japan. </p>
            </list-item>
          </list>
          <table-wrap id="bietti-cd.T.summary_of_molecular_genetic" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Bietti Crystalline Dystrophy </p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_bietti-cd.T.summary_of_molecular_genetic_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_bietti-cd.T.summary_of_molecular_genetic_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_bietti-cd.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mutations Detected&#x000a0;<sup>2</sup></th>
                  <th id="hd_h_bietti-cd.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mutation Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_bietti-cd.T.summary_of_molecular_genetic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">CYP4V2</italic>
                  </td>
                  <td headers="hd_h_bietti-cd.T.summary_of_molecular_genetic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_bietti-cd.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                  <td headers="hd_h_bietti-cd.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;93%&#x000a0;<sup>5,&#x000a0;6</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="bietti-cd.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="bietti-cd" object-id="bietti-cd.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. </p>
              </fn>
              <fn id="bietti-cd.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="bietti-cd.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants. </p>
              </fn>
              <fn id="bietti-cd.TF.1.3">
                <label>3. </label>
                <p>The ability of the test method used to detect a mutation that is present in the indicated gene</p>
              </fn>
              <fn id="bietti-cd.TF.1.4">
                <label>4. </label>
                <p>Examples of variants detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site mutations; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="bietti-cd.TF.1.5">
                <label>5. </label>
                <p>Pathogenic variants were identified in 95.4% (N=109) families or 93.6% of alleles [<xref ref-type="bibr" rid="bietti-cd.REF.xiao.2011.181">Xiao et al 2011</xref>].</p>
              </fn>
              <fn id="bietti-cd.TF.1.6">
                <label>6. </label>
                <p>In a study from Japan, eight probands were found to have mutation of <italic toggle="yes">CYP4V2</italic> including seven with the IVS6-8_c.810del/insGC variant, suggesting a founder effect.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="bietti-cd.Testing_Strategy">
          <title>Testing Strategy </title>
          <p><bold>To confirm/establish the diagnosis in a proband.</bold> In the majority of probands, the diagnosis can be established or suspected following standard evaluation procedures for inherited retinal disorders, which typically include past medical history, full ophthalmologic evaluation, visual field testing, spectral domain OCT (sdOCT), and, if available and indicated, electrophysiology. </p>
          <p>Molecular testing (sequence analysis) of <italic toggle="yes">CYP4V2</italic> confirms the clinical diagnosis in a majority of cases.</p>
          <p><bold>Carrier testing for at-risk relatives</bold> requires prior identification of the pathogenic variants in the family.</p>
          <p>Note: Carriers are heterozygotes for this autosomal recessive disorder and are not at risk of developing the disorder.</p>
          <p><bold>Predictive testing</bold> for at-risk asymptomatic adult family members requires prior identification of the pathogenic variants in the family.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variants in the family.</p>
        </sec>
      </sec>
      <sec id="bietti-cd.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="bietti-cd.Clinical_Description">
          <title>Clinical Description</title>
          <p>Bietti crystalline dystrophy (BCD) is a progressive chorioretinal degeneration with onset typically during second to third decade of life, but ranging from the early teenage years to beyond the third decade. The symptoms, ranges of visual impairment, and disabilities are similar to those of individuals with autosomal recessive <related-object link-type="booklink" source-id="gene" document-id="rp-overview" document-type="chapter">retinitis pigmentosa</related-object>. </p>
          <p>The presenting symptom, rate of disease progression, and disease severity are also highly variable in BCD, even among those of the same age, within the same family, and with the same <italic toggle="yes">CYP4V2</italic> mutation [<xref ref-type="bibr" rid="bietti-cd.REF.lee.2005.3812">Lee et al 2005</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.lin.2005.e38">Lin et al 2005</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.xiao.2011.181">Xiao et al 2011</xref>]. </p>
          <p>The progressive atrophy and degeneration of the RPE/choroid leads to reduced visual acuity, poor night vision, abnormal retinal electrophysiology, and visual field constriction. Persons with BCD may also have impaired color vision. In early or milder stages of disease patients can drive a car; however, with time, loss of peripheral visual field, central acuity, or both result in legal blindness in most, if not all, affected individuals. </p>
          <p>Whereas affected individuals typically have profound vision loss by the fifth or sixth decade of life, central acuity can be spared through late stages of the disease in some [<xref ref-type="bibr" rid="bietti-cd.REF.kaiserkupfer.1994.569">Kaiser-Kupfer et al 1994</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.lee.2005.3812">Lee et al 2005</xref>]. A recent study involving 21 families with BCD showed visual acuities ranging from normal to hand motion [<xref ref-type="bibr" rid="bietti-cd.REF.xiao.2011.181">Xiao et al 2011</xref>]. </p>
          <p>Visual field constriction is progressive and usually presents as scotomas that enlarge with progression of disease; central, paracentral, and ring scotomas are common. </p>
          <p>Marked asymmetry between eyes with respect to fundus appearance, reduction in visual acuity, and visual field loss is not uncommon. </p>
          <p>Additional potential retinal complications of BCD include choroidal neovascularization (CNV) [<xref ref-type="bibr" rid="bietti-cd.REF.atmaca.2007.839">Atmaca et al 2007</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.gupta.2011.59">Gupta et al 2011</xref>] and macular hole [<xref ref-type="bibr" rid="bietti-cd.REF.zhu.2009.660">Zhu et al 2009</xref>]. </p>
        </sec>
        <sec id="bietti-cd.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations </title>
          <p>Individuals with BCD who are homozygous for the <xref ref-type="table" rid="bietti-cd.T.selected_cyp4v2_pathogenic_a">c.800-1_8delTCATACAG_800_808delGTCATCGCGinsGC</xref> allele or compound heterozygous for this allele along with <xref ref-type="table" rid="bietti-cd.T.selected_cyp4v2_pathogenic_a">c.1091-1A&#x0003e;G</xref> appear to have a more severe form of the disease based on electrophysiologic testing. The level of visual loss in BCD is related to the severity of retinal thinning [<xref ref-type="bibr" rid="bietti-cd.REF.lai.2007.5212">Lai et al 2007</xref>].</p>
          <p>Individuals with splice site mutations (i.e., homozygous <xref ref-type="table" rid="bietti-cd.T.selected_cyp4v2_pathogenic_a">c.800-1_8delTCATACAG_800_808delGTCATCGCGinsGC</xref> or compound heterozygous c.800-1_8delTCATACAG_800_808delGTCATCGCGinsGC and <xref ref-type="table" rid="bietti-cd.T.selected_cyp4v2_pathogenic_a">c.1091-1A&#x0003e;G</xref>) had lower EOG Arden indices and were more likely to have a nonrecordable scotopic full-field ERG and 30-Hz flicker ERG when compared with individuals harboring coding region mutations. </p>
          <p>The high degree of clinical variability in BCD suggests that influencing factors, other than the primary <italic toggle="yes">CYP4V2</italic> defect, may be at play. The uncommon cases that are regional (i.e., affect only certain regions of the retina) may represent disease associated with pathogenic variants that are associated with retention of either a small amount of functional gene product or other modifying factors. There is no evidence to suggest that mutation of any gene other than <italic toggle="yes">CYP4V2</italic> causes BCD.</p>
        </sec>
        <sec id="bietti-cd.Prevalence">
          <title>Prevalence </title>
          <p>While BCD is generally considered to be a rare disease, it may be underdiagnosed. For example, in a study done by Mataftsi et al, approximately 10% of persons with autosomal recessive retinitis pigmentosa were also diagnosed with BCD [<xref ref-type="bibr" rid="bietti-cd.REF.mataftsi.2004.416">Mataftsi et al 2004</xref>]. According to Hartong et al, worldwide prevalence of retinitis pigmentosa was one in 4000, with autosomal recessive retinitis pigmentosa accounting for 50%-60% of the cases [<xref ref-type="bibr" rid="bietti-cd.REF.hartong.2006.1795">Hartong et al 2006</xref>]. This implies a prevalence of BCD up to one in 67,000, representing almost 5,000 individuals in the US alone.</p>
          <p>BCD appears to be more common in people of East Asian descent, particularly the Chinese and Japanese [<xref ref-type="bibr" rid="bietti-cd.REF.hu.1983.39">Hu 1983</xref>]. It has also been reported in persons of Lebanese and Mexican origin [<xref ref-type="bibr" rid="bietti-cd.REF.lin.2005.e38">Lin et al 2005</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.lai.2007.5212">Lai et al 2007</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.zenteno.2008.313">Zenteno et al 2008</xref>] and in persons of European origin presenting with retinitis pigmentosa [<xref ref-type="bibr" rid="bietti-cd.REF.mataftsi.2004.416">Mataftsi et al 2004</xref>]. </p>
        </sec>
      </sec>
      <sec id="bietti-cd.Genetically_Related_Allelic_Di">
        <title>Genetically Related (Allelic) Disorders </title>
        <p>A common single nucleotide variant (SNV) of <italic toggle="yes">CYP4V2</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&#x00026;db=Nucleotide&#x00026;term=NM_207352.3">NM_207352.3</ext-link>:c.775C&#x0003e;A, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=13146272">rs13146272</ext-link>, p.Gln259Lys) has emerged as a risk factor in deep venous thromboembolism (DVT) [<xref ref-type="bibr" rid="bietti-cd.REF.bezemer.2008.1306">Bezemer et al 2008</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.li.2009.1802">Li et al 2009</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.tr_gou_t.2009.5298">Tr&#x000e9;gou&#x000eb;t et al 2009</xref>]. The association was confirmed in a recent meta-analysis of five replication cohorts [<xref ref-type="bibr" rid="bietti-cd.REF.austin.2011.489">Austin et al 2011</xref>]. c.775C&#x0003e;A is in linkage disequilibrium with SNVs in <italic toggle="yes">F11</italic> (encoding factor XI) and <italic toggle="yes">KLKB1</italic> (encoding pre-kallikrein), proteins known to be involved in coagulation. Initially this was thought to explain, at least in part, the observed association of c.775C&#x0003e;A with DVT; however, more detailed genetic analysis indicated that persons possessing the A-C-T haplotype corresponding to <italic toggle="yes">CYP4V2</italic> c.775C&#x0003e;A, <italic toggle="yes">F11</italic>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2036914">rs2036914</ext-link>, and <italic toggle="yes">F11</italic>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2289252">rs2289252</ext-link> were at highest risk for DVT (odds ratio: 1.55-1.57) [<xref ref-type="bibr" rid="bietti-cd.REF.li.2009.1802">Li et al 2009</xref>], indicating an essential modulating influence of <italic toggle="yes">CYP4V2</italic> mutation c.775C&#x0003e;A on the two more directly-acting <italic toggle="yes">F11</italic> SNVs. </p>
      </sec>
      <sec id="bietti-cd.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><bold>Retinitis pigmentosa</bold>. The clinical symptoms and findings on visual field testing and electrophysiologic studies in Bietti crystalline dystrophy (BCD) are similar to those of other forms of retinal degeneration that fall under the category of retinitis pigmentosa and allied disorders. See <related-object link-type="booklink" source-id="gene" document-id="rp-overview" document-type="chapter">Retinitis Pigmentosa Overview</related-object>. </p>
        <p>Crystalline deposits in the retina may be associated with:</p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="ph1" document-type="chapter">Primary hyperoxaluria type 1</related-object> and <related-object link-type="booklink" source-id="gene" document-id="ph2" document-type="chapter">primary hyperoxaluria type 2</related-object></p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="ctns" document-type="chapter">Cystinosis</related-object>
            </p>
          </list-item>
          <list-item>
            <p>Sj&#x000f6;gren-Larsson syndrome (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/270200">270200</ext-link>)</p>
          </list-item>
          <list-item>
            <p>Drug toxicity (e.g., tamoxifen, the anesthetic methoxyflurane, the oral tanning agent canthaxanthine) </p>
          </list-item>
          <list-item>
            <p>Drug abuse (talc retinopathy)</p>
          </list-item>
        </list>
      </sec>
      <sec id="bietti-cd.Management_1">
        <title>Management</title>
        <sec id="bietti-cd.Evaluations_Following_Initial">
          <title>Evaluations Following Initial Diagnosis </title>
          <p>To establish the extent of disease and needs of an individual diagnosed with Bietti crystalline dystrophy (BCD), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Fundoscopic examination</p>
            </list-item>
            <list-item>
              <p>Full-field electroretinogram (ffERG) to establish a baseline</p>
            </list-item>
            <list-item>
              <p>Visual field testing (perimetry) to evaluate the degree of visual field constriction or presence of scotomas and to establish a baseline</p>
            </list-item>
            <list-item>
              <p>Optical coherence tomography (OCT) to evaluate for complications such as choroidal neovascularization (CNV) or macular hole formation</p>
            </list-item>
            <list-item>
              <p>Medical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="bietti-cd.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>No treatment for BCD currently exists; affected individuals should be referred to services specific to those with vision impairment:</p>
          <list list-type="bullet">
            <list-item>
              <p>Low vision specialists can prescribe low vision aids/devices to help optimize remaining vision.</p>
            </list-item>
            <list-item>
              <p>State services for the Blind or organizations/professionals trained to work with the visually impaired provide access to services related to employment, education, and counseling regarding the psychosocial adaptation to visual loss </p>
            </list-item>
          </list>
          <p>Note: Choroidal neovascularization (CNV) is uncommon in BCD. Laser photocoagulation is not usually considered for CNV in inherited forms of retinal degeneration and has recently been superseded by the use of anti-vascular endothelial growth factor (anti-VEGF) therapy in a fashion similar to its use in age-related macular dystrophy.</p>
        </sec>
        <sec id="bietti-cd.Surveillance">
          <title>Surveillance</title>
          <p>Ophthalmologic examination is recommended every one to two years to monitor disease progression. Examination should include visual field testing particularly as it relates to determination of driving eligibility and eligibility for government programs and/or disability. </p>
          <p>Patients should be aware of the possibility of choroidal neovascularization (CNV) and the option of self-monitoring using an Amsler grid under direction of their primary care ophthalmologist.</p>
        </sec>
        <sec id="bietti-cd.Evaluation_of_Relatives_at_Ris">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="bietti-cd.Related_Genetic_Counseling_Iss">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="bietti-cd.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ClinicalTrials.gov">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="bietti-cd.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="bietti-cd.Mode_of_Inheritance">
          <title>Mode of Inheritance </title>
          <p>Bietti crystalline dystrophy (BCD) is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="bietti-cd.Risk_to_Family_Members">
          <title>Risk to Family Members </title>
          <p><bold>Parents of a proband</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one mutant allele).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p><bold>Sibs of a proband</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. </p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3. </p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with Bietti crystalline dystrophy are obligate heterozygotes (carriers) for a disease-causing mutation in <italic toggle="yes">CYP4V2</italic>. </p>
          <p>Unless an individual with Bietti crystalline dystrophy has children with an affected individual or a carrier, his/her offspring will be obligate heterozygotes (carriers) for a disease-causing mutation in <italic toggle="yes">CYP4V2</italic>. </p>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier. </p>
        </sec>
        <sec id="bietti-cd.Carrier_Detection">
          <title>Carrier Detection </title>
          <p>Carrier testing of at-risk relatives is possible if the pathogenic variants in the family have been identified. </p>
        </sec>
        <sec id="bietti-cd.Related_Genetic_Counseling_Iss">
          <title>Related Genetic Counseling Issues </title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy. </p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals. </p>
        </sec>
        <sec id="bietti-cd.Prenatal_Testing">
          <title>Prenatal Testing </title>
          <p>Prenatal diagnosis for pregnancies at increased risk is possible by analysis of DNA extracted from fetal cells obtained by amniocentesis usually performed at approximately 15 to 18 weeks&#x02019; gestation or chorionic villus sampling (CVS) at approximately ten to 12 weeks&#x02019; gestation. The pathogenic variants in the family must be identified before prenatal testing can be performed.</p>
          <p>Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.</p>
          <p>Requests for prenatal testing for conditions such as Bietti crystalline dystrophy are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although decisions about prenatal testing are the choice of the parents, discussion of these issues is appropriate.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the pathogenic variants have been identified. </p>
        </sec>
      </sec>
      <sec id="bietti-cd.Resources">
        <title>Resources</title>
      </sec>
      <sec id="bietti-cd.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="bietti-cd.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis </title>
          <p>Though the biochemical basis of BCD remains unknown, findings suggest that BCD may result from a systemic abnormality in lipid metabolism. There also have been reports of a missing 32-kd fatty-acid binding protein with a high affinity for fatty acids: docosahexaenoic acid (DHA; 22:6n-3), &#x003b1;-linolenic acid (18:3n-3), and palmitic acid (16:0) in the lymphocytes of persons with BCD compared to controls [<xref ref-type="bibr" rid="bietti-cd.REF.lee.1998.143">Lee et al 1998</xref>]. Metabolic studies of fibroblasts and lymphocytes cultured from individuals with BCD exhibited altered lipid metabolism, with decreased synthesis of &#x003c9;-3 polyunsaturated fatty acids (PUFAs) (e.g., eicosapentaenoic acid (EPA; 20:5n-3) and DHA) from &#x003b1;-linolenic acid compared to controls [<xref ref-type="bibr" rid="bietti-cd.REF.lee.2001.1707">Lee et al 2001</xref>]. </p>
          <p>More recently, free fatty acid profiling revealed significantly altered fatty acid concentrations in the serum of persons with BCD compared to controls. Specifically, stearic acid (18:0) was elevated and oleic acid (18:1n-9) was lowered in persons with BCD compared to controls [<xref ref-type="bibr" rid="bietti-cd.REF.lai.2010.1092">Lai et al 2010</xref>]. </p>
          <p>In addition to ocular tissues, transmission electron microscopy showed crystalline material of unknown lipid composition in lymphoblasts and fibroblasts of persons with BCD [<xref ref-type="bibr" rid="bietti-cd.REF.welch.1977.164">Welch 1977</xref>]. </p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">CYP4V2</italic> spans 19 kb and comprises 11 exons [<xref ref-type="bibr" rid="bietti-cd.REF.li.2004.817">Li et al 2004</xref>]. Genetic linkage analysis first identified the BCD locus to be located on human chromosome 4q35 [<xref ref-type="bibr" rid="bietti-cd.REF.jiao.2000.1309">Jiao et al 2000</xref>]. Fine mapping of this locus identified <italic toggle="yes">CYP4V2</italic> as the gene in which mutation is responsible for BCD [<xref ref-type="bibr" rid="bietti-cd.REF.li.2004.817">Li et al 2004</xref>]. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="bietti-cd" object-id="bietti-cd.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Pathogenic allelic variants.</bold> A wide range of <italic toggle="yes">CYP4V2</italic> pathogenic variants (&#x0003e;30) have now been described in individuals with BCD. At least one pathogenic variant has been reported in each of the 11 exons. See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="bietti-cd-Table3.pdf" content-type="local-data">Table 3</inline-supplementary-material> (pdf). </p>
          <p>The most frequent <italic toggle="yes">CYP4V2</italic> pathogenic variant found in affected individuals, c.800-1_8delTCATACAG_800_808delGTCATCGCGinsGC, results in the skipping of exon 7. Eight nucleotides of the 3&#x02019; end of intron 6 and nine from the 5&#x02019; end of exon 7 are deleted along with an insertion of GC [<xref ref-type="bibr" rid="bietti-cd.REF.bietti.1937.21">Bietti 1937</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.kaiserkupfer.1994.569">Kaiser-Kupfer et al 1994</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.lee.1998.143">Lee et al 1998</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.lee.2001.1707">Lee et al 2001</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.lewis.2004.305">Lewis 2004</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.shan.2005.738">Shan et al 2005</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.baer.2006.451">Baer &#x00026; Rettie 2006</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.hardwick.2008.2263">Hardwick 2008</xref>]. </p>
          <p>Two other deletions, c.1091-1A&#x0003e;G and c.1226-6delTGACAG_1226_1235delCAGGTTACAG (a deletion spanning the splice acceptor site for exon 9), result in skipping of exons 9 and 10, respectively [<xref ref-type="bibr" rid="bietti-cd.REF.li.2004.817">Li et al 2004</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.shan.2005.738">Shan et al 2005</xref>].</p>
          <p>Six more nonsense mutations and 23 missense mutations have also been described [<xref ref-type="bibr" rid="bietti-cd.REF.li.2004.817">Li et al 2004</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.lee.2005.3812">Lee et al 2005</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.lin.2005.e38">Lin et al 2005</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.shan.2005.738">Shan et al 2005</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.wada.2005.894">Wada et al 2005</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.lai.2007.5212">Lai et al 2007</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.hardwick.2008.2263">Hardwick 2008</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.zenteno.2008.313">Zenteno et al 2008</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.xiao.2011.181">Xiao et al 2011</xref>]. </p>
          <table-wrap id="bietti-cd.T.selected_cyp4v2_pathogenic_a" position="anchor" orientation="portrait">
            <label>Table 2. </label>
            <caption>
              <p>Selected <italic toggle="yes">CYP4V2</italic> Pathogenic Allelic Variants </p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_bietti-cd.T.selected_cyp4v2_pathogenic_a_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>) </th>
                  <th id="hd_h_bietti-cd.T.selected_cyp4v2_pathogenic_a_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                  <th id="hd_h_bietti-cd.T.selected_cyp4v2_pathogenic_a_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_bietti-cd.T.selected_cyp4v2_pathogenic_a_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.327+1G&#x0003e;A<break/>(IVS2+1G&#x0003e;A)</td>
                  <td headers="hd_h_bietti-cd.T.selected_cyp4v2_pathogenic_a_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">See footnote 2</td>
                  <td headers="hd_h_bietti-cd.T.selected_cyp4v2_pathogenic_a_1_1_1_3" rowspan="4" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&#x00026;db=Nucleotide&#x00026;term=NM_207352.3">NM_207352.3</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&#x00026;db=protein&#x00026;term=NP_997235.3">NP_997235.3</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_bietti-cd.T.selected_cyp4v2_pathogenic_a_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.800-1_8delTCATACAG_800_808delGTCATCGCGinsGC&#x000a0;<sup>3</sup><break/>(IVS6-8 del/insGC)</td>
                  <td headers="hd_h_bietti-cd.T.selected_cyp4v2_pathogenic_a_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">See footnote 3</td>
                </tr>
                <tr>
                  <td headers="hd_h_bietti-cd.T.selected_cyp4v2_pathogenic_a_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1091-1A&#x0003e;G<break/>(ISV8-2A&#x0003e;G)</td>
                  <td headers="hd_h_bietti-cd.T.selected_cyp4v2_pathogenic_a_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">See footnote 4 </td>
                </tr>
                <tr>
                  <td headers="hd_h_bietti-cd.T.selected_cyp4v2_pathogenic_a_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1226-6delTGACAG_1226_1235delCAGGTTACAG&#x000a0;<sup>5</sup><break/>(IVS9-6del)</td>
                  <td headers="hd_h_bietti-cd.T.selected_cyp4v2_pathogenic_a_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">See footnote 5</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants. </p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature. </p>
              </fn>
              <fn id="bietti-cd.TF.2.1">
                <label>1. </label>
                <p>Variant designation that does not conform to current naming conventions</p>
              </fn>
              <fn id="bietti-cd.TF.2.2">
                <label>2. </label>
                <p>Skipping of exon 2, resulting in a frameshift in which the exon 1 sequence is followed by four novel amino acids and a premature terminating [<xref ref-type="bibr" rid="bietti-cd.REF.li.2004.817">Li et al 2004</xref>]. </p>
              </fn>
              <fn id="bietti-cd.TF.2.3">
                <label>3. </label>
                <p>Skipping of exon 7, which encodes 62 amino acids [<xref ref-type="bibr" rid="bietti-cd.REF.wada.2005.894">Wada et al 2005</xref>]</p>
              </fn>
              <fn id="bietti-cd.TF.2.4">
                <label>4. </label>
                <p>Skipping of exon 9, which encodes 62 amino acids </p>
              </fn>
              <fn id="bietti-cd.TF.2.5">
                <label>5. </label>
                <p>Skipping of exon 10, which encodes 60 amino acids [<xref ref-type="bibr" rid="bietti-cd.REF.shan.2005.738">Shan et al 2005</xref>]</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> The cytochrome P450 4V2 protein (CYP4V2) is 525 amino acids. This protein is a member of the CYP superfamily of heme-containing monooxygenases. CYP4V2 is a fatty acid oxidase, with preferential activity for &#x003c9;-hydroxylation of saturated, medium-chain fatty acids [<xref ref-type="bibr" rid="bietti-cd.REF.nakano.2009.2119">Nakano et al 2009</xref>]. Homology modeling predicts that the CYP4V2 structure contains a transmembrane segment located near the amino terminus with a globular structural domain following that is typical of cytochrome P450 enzymes. The globular domain of CYP4V2 comprises 18 helices and &#x003b2; structural elements [<xref ref-type="bibr" rid="bietti-cd.REF.li.2004.817">Li et al 2004</xref>]</p>
          <p><bold>Abnormal gene product.</bold> There is no published evidence that the abnormal gene product causes disease through loss of function. </p>
          <p>Pathogenic variants resulting from exon 7, 9, and 10 skipping and pathogenic variants resulting from the exon 2 splicing that predicts premature termination are expected to cause gross structural changes in any translated protein with resulting loss of enzyme activity. </p>
          <p>Similarly, several amino acid deletions and substitutions would be predicted to negatively affect CYP4V2 activity, based on their conservation across other CYP4 enzymes and homology modeling [<xref ref-type="bibr" rid="bietti-cd.REF.li.2004.817">Li et al 2004</xref>]. </p>
          <p>Exon-skipping mutations are predicted to lead to more severe forms of the disease than are missense mutations, which lead to homozygous or heterozygous amino acid substitutions [<xref ref-type="bibr" rid="bietti-cd.REF.li.2004.817">Li et al 2004</xref>, <xref ref-type="bibr" rid="bietti-cd.REF.lai.2007.5212">Lai et al 2007</xref>]. </p>
          <p>Defects in the catalytic function of this enzyme lead to altered fatty acid metabolism; the endogenous substrate(s) have yet to be identified.</p>
        </sec>
      </sec>
      <sec id="bietti-cd.References">
        <title>References</title>
        <sec id="bietti-cd.Literature_Cited">
          <title>Literature Cited </title>
          <ref-list id="bietti-cd.Literature_Cited.reflist0">
            <ref id="bietti-cd.REF.atmaca.2007.839">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Atmaca</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muftuoglu</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Atmaca-Sonmez</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Peripapillary choroidal neovascularization in Bietti crystalline retinopathy.</article-title>
                <source>Eye (Lond)</source>
                <volume>21</volume>
                <fpage>839</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">17173010</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.austin.2011.489">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Austin</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Staercke</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lally</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bezemer</surname>
                    <given-names>ID</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosendaal</surname>
                    <given-names>FR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hooper</surname>
                    <given-names>WC</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>New gene variants associated with venous thrombosis: a replication study in White and Black Americans.</article-title>
                <source>J Thromb Haemost.</source>
                <volume>9</volume>
                <fpage>489</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">21232005</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.baer.2006.451">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baer</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rettie</surname>
                    <given-names>AE</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>CYP4B1: an enigmatic P450 at the interface between xenobiotic and endobiotic metabolism.</article-title>
                <source>Drug Metab Rev.</source>
                <volume>38</volume>
                <fpage>451</fpage>
                <lpage>76</lpage>
                <pub-id pub-id-type="pmid">16877261</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.bezemer.2008.1306">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bezemer</surname>
                    <given-names>ID</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bare</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doggen</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arellano</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tong</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rowland</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Catanese</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reitsma</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Devlin</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosendaal</surname>
                    <given-names>FR</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Gene variants associated with deep vein thrombosis.</article-title>
                <source>JAMA</source>
                <volume>299</volume>
                <fpage>1306</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">18349091</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.bietti.1937.21">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bietti</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1937</year>
                <article-title>Ueber familiaeres vorkommen von &#x0201c;retinitis punctata albescens&#x0201d; (verbunden mit &#x0201c;dystrophia marginalis cristallinea corneae&#x0201d;), glitzern des glaskoerpers und anderen degenerativen augenveraenderungen.</article-title>
                <source>Klin Mbl Augenheilk</source>
                <volume>99</volume>
                <fpage>21</fpage>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.chen.2008.237">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Functional and clinical findings in 3 female siblings with crystalline retinopathy.</article-title>
                <source>Doc Ophthalmol.</source>
                <volume>116</volume>
                <fpage>237</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">17962988</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.gupta.2011.59">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gupta</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parvizi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohamed</surname>
                    <given-names>MD</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Bietti crystalline dystrophy and choroidal neovascularisation.</article-title>
                <source>Int Ophthalmol.</source>
                <volume>31</volume>
                <fpage>59</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">20972604</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.hardwick.2008.2263">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hardwick</surname>
                    <given-names>JP</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases.</article-title>
                <source>Biochem Pharmacol.</source>
                <volume>75</volume>
                <fpage>2263</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">18433732</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.hartong.2006.1795">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hartong</surname>
                    <given-names>DT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berson</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dryja</surname>
                    <given-names>TP</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Retinitis pigmentosa.</article-title>
                <source>Lancet.</source>
                <volume>368</volume>
                <fpage>1795</fpage>
                <lpage>809</lpage>
                <pub-id pub-id-type="pmid">17113430</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.hu.1983.39">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hu</surname>
                    <given-names>DN</given-names>
                  </name>
                </person-group>
                <year>1983</year>
                <article-title>Ophthalmic genetics in China.</article-title>
                <source>Ophthal Paediat Genet.</source>
                <volume>2</volume>
                <fpage>39</fpage>
                <lpage>45</lpage>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.jiao.2000.1309">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jiao</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munier</surname>
                    <given-names>FL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iwata</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayakawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanai</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schorderet</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaiser-Kupfer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hejtmancik</surname>
                    <given-names>JF</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Genetic linkage of Bietti crystallin corneoretinal dystrophy to chromosome 4q35.</article-title>
                <source>Am J Hum Genet.</source>
                <volume>67</volume>
                <fpage>1309</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">11001583</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.kaiserkupfer.1994.569">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kaiser-Kupfer</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Markello</surname>
                    <given-names>TC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crawford</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caruso</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Csaky</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guo</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Clinical biochemical and pathologic correlations in Bietti's crystalline dystrophy.</article-title>
                <source>Am J Ophthalmol.</source>
                <volume>118</volume>
                <fpage>569</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">7977570</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.kojima.2012.390">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kojima</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogino</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakagawa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makiyama</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurimoto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshimura</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Outer retinal circular structures in patients with Bietti crystalline retinopathy.</article-title>
                <source>Br J Ophthalmol.</source>
                <volume>96</volume>
                <fpage>390</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">21803923</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.lai.2010.1092">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lai</surname>
                    <given-names>TY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chu</surname>
                    <given-names>KO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>KP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ng</surname>
                    <given-names>TK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yam</surname>
                    <given-names>GH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lam</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pang</surname>
                    <given-names>CP</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Alterations in serum fatty acid concentrations and desaturase activities in Bietti crystalline dystrophy unaffected by CYP4V2 genotypes.</article-title>
                <source>Invest Ophthalmol Vis Sci.</source>
                <volume>51</volume>
                <fpage>1092</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">19797200</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.lai.2007.5212">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lai</surname>
                    <given-names>TY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ng</surname>
                    <given-names>TK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tam</surname>
                    <given-names>PO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yam</surname>
                    <given-names>GH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ngai</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>WM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>DT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lam</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pang</surname>
                    <given-names>CP</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Genotype phenotype analysis of Bietti's crystalline dystrophy in patients with CYP4V2 mutations.</article-title>
                <source>Invest Ophthalmol Vis Sci.</source>
                <volume>48</volume>
                <fpage>5212</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">17962476</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.lee.1998.143">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jiao</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hejtmancik</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaiser-Kupfer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chader</surname>
                    <given-names>GJ</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Identification, isolation, and characterization of a 32-kDa fatty acid-binding protein missing from lymphocytes in humans with Bietti crystalline dystrophy (BCD).</article-title>
                <source>Mol Genet Metab.</source>
                <volume>65</volume>
                <fpage>143</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">9787106</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.lee.2001.1707">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jiao</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hejtmancik</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaiser-Kupfer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Markello</surname>
                    <given-names>TC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guo</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chader</surname>
                    <given-names>GJ</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>The metabolism of fatty acids in human Bietti crystalline dystrophy.</article-title>
                <source>Invest Ophthalmol Vis Sci.</source>
                <volume>42</volume>
                <fpage>1707</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">11431432</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.lee.2005.3812">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>KY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koh</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aung</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yong</surname>
                    <given-names>VH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yeung</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ang</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vithana</surname>
                    <given-names>EN</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Characterization of Bietti crystalline dystrophy patients with CYP4V2 mutations.</article-title>
                <source>Invest Ophthalmol Vis Sci.</source>
                <volume>46</volume>
                <fpage>3812</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16186368</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.lewis.2004.305">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lewis</surname>
                    <given-names>DF</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>57 varieties: the human cytochromes P450.</article-title>
                <source>Pharmacogenomics.</source>
                <volume>5</volume>
                <fpage>305</fpage>
                <lpage>18</lpage>
                <pub-id pub-id-type="pmid">15102545</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.li.2004.817">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jiao</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munier</surname>
                    <given-names>FL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schorderet</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yao</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iwata</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayakawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanai</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shy Chen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alan Lewis</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heckenlively</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weleber</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Traboulsi</surname>
                    <given-names>EI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xiao</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaiser-Kupfer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sergeev</surname>
                    <given-names>YV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hejtmancik</surname>
                    <given-names>JF</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V2.</article-title>
                <source>Am J Hum Genet.</source>
                <volume>74</volume>
                <fpage>817</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">15042513</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.li.2009.1802">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bezemer</surname>
                    <given-names>ID</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rowland</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tong</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arellano</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Catanese</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Devlin</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reitsma</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bare</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosendaal</surname>
                    <given-names>FR</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Genetic variants associated with deep vein thrombosis: the F11 locus.</article-title>
                <source>J Thromb Haemost.</source>
                <volume>7</volume>
                <fpage>1802</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">19583818</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.lin.2005.e38">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishiguchi</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dryja</surname>
                    <given-names>TP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berson</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyake</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Recessive mutations in the CYP4V2 gene in East Asian and Middle Eastern patients with Bietti crystalline corneoretinal dystrophy.</article-title>
                <source>J Med Genet.</source>
                <volume>42</volume>
                <fpage>e38</fpage>
                <pub-id pub-id-type="pmid">15937078</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.mataftsi.2004.416">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mataftsi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zografos</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mill&#x000e1;</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Secr&#x000e9;tan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munier</surname>
                    <given-names>FL</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Bietti's crystalline corneoretinal dystrophy: a cross-sectional study.</article-title>
                <source>Retina.</source>
                <volume>24</volume>
                <fpage>416</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">15187665</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.mansour.2007.680">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mansour</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uwaydat</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>CC</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Long-term follow-up in Bietti crystalline dystrophy.</article-title>
                <source>Eur J Ophthalmol.</source>
                <volume>17</volume>
                <fpage>680</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">17671952</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.nakano.2009.2119">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nakano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rettie</surname>
                    <given-names>AE</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Expression and characterization of CYP4V2 as a fatty acid omega-hydroxylase.</article-title>
                <source>Drug Metab Dispos.</source>
                <volume>37</volume>
                <fpage>2119</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">19661213</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.padhi.2011.199">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Padhi</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kesarwani</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jalali</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Bietti crystalline retinal dystrophy with subfoveal neurosensory detachment and congenital tortuosity of retinal vessels: case report.</article-title>
                <source>Doc Ophthalmol.</source>
                <year>2011</year>
                <volume>122</volume>
                <fpage>199</fpage>
                <lpage>206</lpage>
                <pub-id pub-id-type="pmid">21611771</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.pennesi.2010.531">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pennesi</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weleber</surname>
                    <given-names>RG</given-names>
                  </name>
                </person-group>
                <article-title>High-resolution optical coherence tomography shows new aspects of Bietti crystalline retinopathy.</article-title>
                <source>Retina.</source>
                <year>2010</year>
                <volume>30</volume>
                <fpage>531</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">20139800</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.rossi.2011.118">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Testa</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iorio</surname>
                    <given-names>VD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gesualdo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corte</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fielding Hejtmancik</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simonelli</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>An atypical form of Bietti crystalline dystrophy.</article-title>
                <source>Ophthalmic Genet.</source>
                <year>2011</year>
                <volume>32</volume>
                <fpage>118</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">21385027</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.shan.2005.738">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dong</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Novel mutations in the CYP4V2 gene associated with Bietti crystalline corneoretinal dystrophy.</article-title>
                <source>Mol Vis.</source>
                <volume>11</volume>
                <fpage>738</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">16179904</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.takikawa.1992.969">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Takikawa</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyake</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>1992</year>
                <article-title>Re-evaluation of cystalline retinopathy based on corneal findings.</article-title>
                <source>Folia Ophthalmol Jpn</source>
                <volume>43</volume>
                <fpage>969</fpage>
                <lpage>78</lpage>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.tr_gou_t.2009.5298">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tr&#x000e9;gou&#x000eb;t</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heath</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saut</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biron-Andreani</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schved</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pernod</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drouet</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zelenika</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Juhan-Vague</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alessi</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiret</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lathrop</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Emmerich</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morange</surname>
                    <given-names>PE</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach.</article-title>
                <source>Blood.</source>
                <volume>113</volume>
                <fpage>5298</fpage>
                <lpage>303</lpage>
                <pub-id pub-id-type="pmid">19278955</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.traboulsi.1987.156">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Traboulsi</surname>
                    <given-names>EI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faris</surname>
                    <given-names>BM</given-names>
                  </name>
                </person-group>
                <year>1987</year>
                <article-title>Crystalline retinopathy.</article-title>
                <source>Ann Ophthalmol.</source>
                <volume>19</volume>
                <fpage>156</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">3619268</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.usui.2001.395">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Usui</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanimoto</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takagi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasegawa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abe</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Rod and cone a-waves in three cases of Bietti crystalline chorioretinal dystrophy.</article-title>
                <source>Am J Ophthalmol.</source>
                <volume>132</volume>
                <fpage>395</fpage>
                <lpage>402</lpage>
                <pub-id pub-id-type="pmid">11530054</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.wada.2005.894">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wada</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Itabashi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sato</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawamura</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tada</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tamai</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Screening for mutations in CYP4V2 gene in Japanese patients with Bietti's crystalline corneoretinal dystrophy.</article-title>
                <source>Am J Ophthalmol.</source>
                <volume>139</volume>
                <fpage>894</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15860296</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.welch.1977.164">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Welch</surname>
                    <given-names>RB</given-names>
                  </name>
                </person-group>
                <year>1977</year>
                <article-title>Bietti's tapetoretinal degeneration with marginal corneal dystrophy crystalline retinopathy.</article-title>
                <source>Trans Am Ophthalmol Soc.</source>
                <volume>75</volume>
                <fpage>164</fpage>
                <lpage>79</lpage>
                <pub-id pub-id-type="pmid">306693</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.weleber.1991">
              <mixed-citation publication-type="book">Weleber RG, Wilson DJ. Bietti's crystalline dystrophy of the cornea and retina. In: Heckenlively JR, Arden GB, eds. <italic toggle="yes">Principles and Practice of Clinical Electrophysiology of Vision.</italic> St Louis, MO: Mosby Year Book; 1991:683-91.</mixed-citation>
            </ref>
            <ref id="bietti-cd.REF.wilson.1989.213">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weleber</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klein</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Welch</surname>
                    <given-names>RB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Green</surname>
                    <given-names>WR</given-names>
                  </name>
                </person-group>
                <year>1989</year>
                <article-title>Bietti's crystalline dystrophy. A clinicopathologic correlative study.</article-title>
                <source>Arch Ophthalmol.</source>
                <volume>107</volume>
                <fpage>213</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">2783846</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.xiao.2011.181">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Xiao</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mai</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guo</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Q</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Identification of CYP4V2 mutation in 21 families and overview of mutation spectrum in Bietti crystalline corneoretinal dystrophy.</article-title>
                <source>Biochem Biophys Res Commun.</source>
                <volume>409</volume>
                <fpage>181</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">21565171</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.zenteno.2008.313">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zenteno</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ayala-Ramirez</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graue-Wiechers</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Novel CYP4V2 gene mutation in a Mexican patient with Bietti's crystalline corneoretinal dystrophy.</article-title>
                <source>Curr Eye Res.</source>
                <volume>33</volume>
                <fpage>313</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">18398705</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.zhu.2009.660">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhu</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ji</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ke</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Posterior scleral reinforcement in the treatment of macular retinoschisis in highly myopic patients.</article-title>
                <source>Clin Experiment Ophthalmol.</source>
                <year>2009</year>
                <volume>37</volume>
                <fpage>660</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">19788661</pub-id>
              </element-citation>
            </ref>
            <ref id="bietti-cd.REF.zweifel.2009.1596">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zweifel</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Engelbert</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laud</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margolis</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spaide</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freund</surname>
                    <given-names>KB</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Outer retinal tubulation: a novel optical coherence tomography finding.</article-title>
                <source>Arch Ophthalmol.</source>
                <volume>127</volume>
                <fpage>1596</fpage>
                <lpage>602</lpage>
                <pub-id pub-id-type="pmid">20008714</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="bietti-cd.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="bietti-cd.Suggested_Reading.reflist0">
            <ref id="bietti-cd.REF.nakamura.2006.49">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishiguchi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugita</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyake</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Bietti crystalline corneoretinal dystrophy associated with CYP4V2 gene mutations.</article-title>
                <source>Adv Exp Med Biol.</source>
                <volume>572</volume>
                <fpage>49</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">17249554</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="bietti-cd.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="bietti-cd.Author_Notes">
          <title>Author Notes </title>
          <p>For interested parties:</p>
          <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://sop.washington.edu/about/directory/name/edward-kelly-2/">Ed Kelly's Web site</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ohsu.edu/xd/research/research-expertise/researchers/weleberr.cfm">Dick Weleber's Web site</ext-link>
</p>
        </sec>
        <sec id="bietti-cd.Acknowledgments">
          <title>Acknowledgments </title>
          <p>Supported in part by a Center Grant from Foundation Fighting Blindness, Columbia, MD) and an unrestricted grant from Research to Prevent Blindness (New York, NY)</p>
        </sec>
        <sec id="bietti-cd.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>14 June 2012 (cd) Revision: prenatal testing available</p>
            </list-item>
            <list-item>
              <p>12 April 2012 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>31 October 2011 (ek) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
